# TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY

> **NIH NIH R01** · ROSWELL PARK CANCER INSTITUTE · 1987 · $214,064

## Abstract

Monoclonal antibody F36/22 (1gG/3, recognizes a glycoprotein
with Mr of 7001000K) has been shown immunohistochemically to
be reactive with all human common epithelial, ovarian cancers,
while normal ovary expresses no detectable level of immunostain.
Human exfoliated ovarian tumor cells are usually disseminating
throughout the entire peritoneal cavity, and represent an ideal
target for therapeutic manipulation in a confined compartment.
A recently available human ovarian carcinoma xenograft in
female athymic mice, NIH:OVCAR-3, expresses antigen
recognized by monoclonal antibody F36/22 and resembles the
human disease by producing ascites and intra-abdominal
carcinomatosis.  Using monoclonal antibody F36/22 as the probe
and NIH:OVCAR-3 as the in vivo model, we will develop and
evaluate effective radioimmunotherapy for the targeting and
elimination of peritoneal ovarian tumor seedings.  Adriamycin, a
commonly used cytotoxic agent in ovarian cancer, will be
conjugated to monoclonal antibody F36/22 for intracavity
immunochemotherapy of ovarian tumor.  Effectiveness of both
therapies will be potentiated by biological response modifiers.
The proposed approaches to the use of a unique monoclonal
antibody in targeting and therapy of ovarian cancer in a confined
cavity compartment with little or no communication with other
body compartments will generate defined and useful preclinical
information.

## Key facts

- **NIH application ID:** 3175432
- **Project number:** 2R01CA037646-04
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE
- **Principal Investigator:** Tsann Ming Chu
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $214,064
- **Award type:** 2
- **Project period:** 1984-08-15 → 1991-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3175432

## Citation

> US National Institutes of Health, RePORTER application 3175432, TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY (2R01CA037646-04). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3175432. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*